亨特氏症候群治疗市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、按最终用户、按地区和竞争进行细分，2020-2030 年预测

2024 年全球亨特氏症治疗市场价值为 13.4 亿美元，预计到 2030 年将达到 15.5 亿美元，预测期内复合年增长率为 5.43%。亨特氏症，也称为黏多醣贮积症 II (MPS II)，是一种罕见的遗传性疾病，其特征是缺乏一种名为艾杜醣醛酸-2-硫酸酯酶 (I2S) 的酵素。根据美国国立卫生研究院 (NIH) 的数据，大约 7,000 种罕见疾病影响着 2,500 万至 3,000 万美国人。当製药公司看到可获得治疗机会的可行市场时，他们更倾向于投资亨特氏症候群等罕见疾病的研发。这使得可用的治疗选择范围更加广泛，包括新疗法和增强配方。随着市场的扩大，长期获利潜力也随之扩大，吸引进一步的投资。扩大治疗机会的努力通常由患者权益团体推动。

这种酵素的缺乏会导致体内某些复合碳水化合物的积累，进而引起各种身体和认知障碍。

主要市场驱动因素

治疗方法的进步

主要市场挑战

治疗费用高且难以取得

主要市场趋势

扩大治疗机会

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球亨特氏症候群治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗（酵素替代疗法、造血干细胞移植）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美亨特氏症候群治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲亨特氏症候群治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区亨特氏症候群治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲亨特氏症候群治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲亨特氏症候群治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• GSK PLC
• Bayer AG
• Novartis AG
• Pfizer Inc
• Zimmer Biomet Holdings Inc
• Sangamo Therapeutics, Inc.

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Hunter Syndrome Treatment Market was valued at USD 1.34 Billion in 2024 and is expected to reach USD 1.55 Billion by 2030 with a CAGR of 5.43% during the forecast period. Hunter syndrome, also known as mucopolysaccharidosis II (MPS II), is a rare genetic disorder characterized by the deficiency of an enzyme called iduronate-2-sulfatase (I2S). According to the National Institutes of Health (NIH), approximately 7,000 rare diseases collectively impact 25 to 30 million Americans. Pharmaceutical companies are more inclined to invest in research and development efforts for rare diseases like Hunter syndrome when they see a viable market with increased access to treatments. This results in a broader array of treatment options becoming available, including novel therapies and enhanced formulations. As the market expands, so does the potential for long-term profitability, attracting further investment. Efforts to expand access to treatment are often driven by patient advocacy groups.

This enzyme deficiency leads to the accumulation of certain complex carbohydrates in the body, causing various physical and cognitive impairments.

Key Market Drivers

Advancements in Treatment Approaches

The field of rare disease treatment is undergoing a profound transformation, and this is particularly evident in the context of Hunter syndrome, also known as mucopolysaccharidosis II (MPS II). As researchers and pharmaceutical companies strive to innovate and discover more effective therapies, advancements in treatment approaches are playing a pivotal role in driving the growth of the Global Hunter Syndrome Treatment Market. One of the most promising developments in the treatment of Hunter syndrome is gene therapy. Gene therapy involves the introduction of a functional copy of the defective gene responsible for the disease, effectively correcting the genetic mutation at its root. While still in its early stages of development, gene therapy for Hunter syndrome has shown remarkable potential in preclinical studies and early-phase clinical trials. If successful, it could provide a one-time, curative treatment, revolutionizing the landscape of Hunter syndrome care and creating a substantial market demand for this groundbreaking therapy. On August 31, 2022, Denali Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies capable of crossing the blood-brain barrier for neurodegenerative diseases and lysosomal storage disorders, announced new interim results from its Phase 1/2 trial of DNL310 (ETV:IDS) for MPS II (Hunter syndrome). DNL310 is an investigational brain-penetrant enzyme replacement therapy designed to address the cognitive, behavioral, and physical symptoms of Hunter syndrome. The findings were presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Freiburg, Germany.

In the realm of rare diseases, heightened awareness can be a catalyst for transformative change. Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare genetic disorder that has historically faced challenges in diagnosis, treatment, and support. However, a growing emphasis on increasing disease awareness is playing a pivotal role in propelling the growth of the Global Hunter Syndrome Treatment Market. One of the most profound impacts of increased disease awareness is the ability to diagnose Hunter syndrome at an earlier stage. With greater recognition of the condition's signs and symptoms among healthcare professionals, children can be identified and diagnosed earlier in life. This early diagnosis is essential because initiating treatment at a young age can significantly improve outcomes. As more children are diagnosed early, the demand for treatment options grows, driving the expansion of the Hunter Syndrome Treatment Market. On February 15, 2022, JCR Pharmaceuticals Co., Ltd. announced the presentation of multiple datasets showcasing the potential advantages of its investigational therapies for lysosomal storage disorders (LSDs). During a series of oral and poster presentations at the 18th Annual WORLD Symposium in San Diego, California, the company highlighted the therapeutic potential of treatments utilizing J-Brain Cargo, its proprietary technology designed to facilitate drug delivery across the blood-brain barrier (BBB).

Awareness initiatives have not only focused on healthcare providers but have also targeted patients, families, and caregivers. Support networks and advocacy groups play a critical role in providing emotional, educational, and financial assistance to those affected by Hunter syndrome. The empowerment of patients and families through awareness can improve their overall quality of life, foster a sense of community, and encourage engagement with healthcare services and treatments. Increasing awareness extends to the broader medical community, including primary care physicians, pediatricians, and specialists. These healthcare professionals need to recognize the signs of Hunter syndrome and refer patients for appropriate testing and care. Medical education programs and awareness campaigns serve to equip healthcare providers with the knowledge necessary to identify and manage this rare condition.

A crucial aspect of Hunter syndrome treatment advancement is the availability of funding and research initiatives. Greater awareness often translates into increased public and private funding for research into potential therapies, including gene therapy and enzyme replacement therapy. As the scientific community gains deeper insights into the condition, innovative treatment options are developed and brought to the market. Disease awareness campaigns often come hand in hand with advocacy efforts. Patient advocacy groups leverage increased awareness to push for policy changes that benefit individuals with Hunter syndrome. These efforts can lead to improved access to treatment, insurance coverage, and government support. As policies become more favorable, it incentivizes pharmaceutical companies to invest in research and development, ultimately expanding the Hunter Syndrome Treatment Market.

Key Market Challenges

High Treatment Costs and Limited Accessibility

One of the most significant challenges in the Global Hunter Syndrome Treatment Market is the high cost of available therapies, which severely limits accessibility for many patients worldwide. Hunter syndrome is a rare lysosomal storage disorder, and developing therapies for such rare diseases involves substantial research and development costs. Enzyme replacement therapy (ERT), currently the most widely used treatment, comes at an extraordinary financial burden, often costing several hundred thousand dollars per patient annually. For instance, idursulfase (Elaprase), the primary ERT used for Hunter syndrome, is priced at approximately $375,000-$500,000 per year, depending on dosage and country-specific pricing. These costs make it extremely difficult for patients, especially in low- and middle-income countries, to access life-saving treatment.

The high financial burden is further compounded by limited insurance coverage and reimbursement policies. Many healthcare systems, particularly in developing nations, lack the resources to cover expensive rare disease treatments under national health programs. Even in developed countries, insurance providers may deny coverage or place restrictions on treatment eligibility, making it difficult for families to afford continuous therapy. Out-of-pocket expenses can be overwhelming, leading many patients to forgo treatment altogether. Another critical issue is the disparity in treatment availability across different regions. In many parts of Africa, South Asia, and Latin America, access to ERT and other supportive therapies remains scarce due to limited distribution networks and regulatory barriers. Pharmaceutical companies often prioritize markets with higher profitability, neglecting regions where patients have the greatest need but the least ability to pay. The lack of specialized healthcare facilities and trained medical professionals in these areas further exacerbates the problem, as proper diagnosis and treatment administration require significant infrastructure investments. In addition to ERT, emerging gene therapies also pose cost-related challenges. While gene therapy has the potential to provide a one-time curative treatment, the anticipated price of such therapies is expected to exceed millions of dollars per patient.

Key Market Trends

Expanded Access to Treatment

The Global Hunter Syndrome Treatment Market has witnessed remarkable progress in recent years, with expanding access to treatment emerging as a pivotal factor driving this growth. Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare genetic disorder that affects a small but significant number of individuals worldwide. The journey towards improving access to treatment options is significantly impacting the market by offering new hope to those affected by this debilitating condition. As pharmaceutical companies and healthcare providers work together to make Hunter syndrome treatments more accessible, the market is expanding its global reach. Access to treatment is no longer limited to developed countries; it's extending to regions with previously limited access to healthcare resources. This broader geographical market expansion is contributing to the overall growth of the Hunter Syndrome Treatment Market.

Expanding access to treatment translates into improved quality of life for patients living with Hunter syndrome. Accessible treatment options help manage symptoms, slow disease progression, and alleviate discomfort. When individuals with Hunter syndrome experience a better quality of life, they become more active participants in society, which, in turn, boosts the demand for treatments and drives market growth. Rare diseases often impose a significant economic burden on patients and their families. Expanding access to treatment can alleviate some of this burden by providing options for financial support, reimbursement, and insurance coverage. As patients and families face fewer financial obstacles to accessing treatment, they are more likely to seek and continue treatment, further supporting market growth.

These organizations raise awareness, advocate for policy changes, and work with healthcare systems to ensure that individuals with Hunter syndrome can access the care they need. Patient empowerment through advocacy plays a crucial role in pushing for equitable access to treatments, thus fostering market growth. The expansion of access to treatment options often translates into more patients participating in clinical trials. Clinical trials are essential for testing and validating new therapies, and a larger pool of participants enhances the research process. The data generated from these trials can lead to the approval of new treatments, further diversifying the market.

Key Market Players

• Takeda Pharmaceutical Co Ltd
• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• Johnson & Johnson
• GSK PLC
• Bayer AG
• Novartis AG
• Pfizer Inc
• Zimmer Biomet Holdings Inc
• Sangamo Therapeutics, Inc.

Report Scope:

In this report, the Global Hunter Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hunter Syndrome Treatment Market, By Treatment:

• Enzyme Replacement Therapy
• Hematopoietic Stem Cell Transplant

Hunter Syndrome Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Hunter Syndrome Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hunter Syndrome Treatment Market.

Available Customizations:

Global Hunter Syndrome Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hunter Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant)
  • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Hunter Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hunter Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Hunter Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Hunter Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User

7. Europe Hunter Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hunter Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Hunter Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Hunter Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User
  • 7.3.4. France Hunter Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Hunter Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End User

8. Asia-Pacific Hunter Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Hunter Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. India Hunter Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Hunter Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Hunter Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Hunter Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User

9. South America Hunter Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Hunter Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Hunter Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Hunter Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User

10. Middle East and Africa Hunter Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Hunter Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Hunter Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Hunter Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Johnson & Johnson
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Takeda Pharmaceutical Co Ltd
• 14.3. F Hoffmann-La Roche AG
• 14.4. Abbott Laboratories Inc
• 14.5. GSK PLC
• 14.6. Bayer AG
• 14.7. Novartis AG
• 14.8. Pfizer Inc
• 14.9. Zimmer Biomet Holdings Inc
• 14.10. Sangamo Therapeutics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer